Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples

(2016) Denise E Brennan et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation

(2015) Hideki Mori et al.   HELICOBACTER

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

(2013) Kazunari Murakami et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

(2011) Juntaro Matsuzaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy

(2010) Juntaro Matsuzaki et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation

(2009) H. Suzuki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY